MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

Abstract Hepatoblastoma (HB) is the most common pediatric liver malignancy. High-risk patients have poor survival, and current chemotherapies are associated with significant toxicities. Targeted therapies are needed to improve outcomes and patient quality of life. Most HB cases are TP53 wild-type; t...

Full description

Bibliographic Details
Main Authors: Sarah E. Woodfield, Yan Shi, Roma H. Patel, Zhenghu Chen, Aayushi P. Shah, Richard S. Whitlock, Aryana M. Ibarra, Samuel R. Larson, Stephen F. Sarabia, Andrew Badachhape, Zbigniew Starosolski, Ketan B. Ghaghada, Pavel Sumazin, D. Allen Annis, Dolores López-Terrada, Sanjeev A. Vasudevan
Format: Article
Language:English
Published: Nature Portfolio 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-82542-4

Internet

https://doi.org/10.1038/s41598-021-82542-4

Similar Items